🇺🇸 FDA
Pipeline program

new formulations of 611

SSGJ-611-HV-I-02

Phase 1 small_molecule active

Quick answer

new formulations of 611 for Atopic Dermatitis is a Phase 1 program (small_molecule) at Sunshine Biopharma with 1 ClinicalTrials.gov record(s).

Program details

Company
Sunshine Biopharma
Indication
Atopic Dermatitis
Phase
Phase 1
Modality
small_molecule
Status
active

Clinical trials